Xencor Inc. Stock
Price
Target price
€17.50
€17.50
-2.230%
-0.4
-2.230%
€31.70
19.07.24 / Stuttgart Stock Exchange
WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xencor Inc. Stock
A loss of -2.230% shows a downward development for Xencor Inc..
We see a rather positive sentiment for Xencor Inc. with 14 Buy predictions and 1 Sell predictions.
As a result the target price of 31 € shows a very positive potential of 77.14% compared to the current price of 17.5 € for Xencor Inc..
Pros and Cons of Xencor Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | -2.230% | -1.685% | -2.778% | -20.455% | -8.377% | -35.472% | -55.702% |
| Ironwood Pharmaceuticals | -3.250% | 0.000% | 6.250% | -37.696% | -41.667% | -46.396% | - |
| Arrowhead Pharmaceuticals Inc. | 0.550% | 0.892% | 9.053% | -19.766% | -7.599% | -54.889% | -2.910% |
| Novocure Ltd | -1.560% | 2.547% | -5.266% | -51.644% | 18.459% | -89.484% | - |
Comments
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at Raymond James from $58.00 to $40.00. They now have a "strong-buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at BMO Capital Markets from $34.00 to $32.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at Royal Bank of Canada from $32.00 to $31.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive
Xencor Reports First Quarter 2024 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of